Sarepta Therapeutics and University of Western Australia

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy

CAMBRIDGE, MA and PERTH, AUSTRALIA--(Marketwired - Apr 11, 2013) - Sarepta Therapeutics, Inc. ( NASDAQ : SRPT ) and the University of Western Australia (UWA) today announced that they have entered into an exclusive, worldwide licensing agreement for intellectual property rights to support the development of exon-skipping drug candidates for the treatment of Duchenne muscular dystrophy (DMD). The agreement grants Sarepta rights to UWA's extensive patent portfolio in DMD and enables the Company to build out its exon-skipping pipeline with new candidates based on its proprietary phosphorodiamidate morpholino oligomer (PMO) technology to address the majority of patients with the disorder worldwide. The deal expands an agreement first signed in 2008, which supported the development of several exon-skipping drugs including eteplirsen, Sarepta's lead clinical candidate for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.

"This agreement underscores our commitment to pursue treatments for all DMD patients who can benefit from our exon-skipping technology, even those with rare genetic mutations," said Chris Garabedian, President and Chief Executive Officer of Sarepta Therapeutics. "We believe this collaboration allows us to apply our unique morpholino chemistry with UWA's groundbreaking research on the dystrophin gene to develop potentially best-in-class drugs for this disease across the globe."

"We are very encouraged by the recent progress of Sarepta's lead clinical program eteplirsen, which we believe demonstrates the strength of the underlying platform technology as well as our partner's drug development expertise in DMD," said Andy Sierakowski, Ph.D., Director of the Office of Industry and Innovation at UWA. "This expanded collaboration with Sarepta enables us to translate our understanding of the dystrophin gene into additional potential exon-skipping therapeutics that address a majority of patients with DMD, representing a major contribution by the University of Western Australia to the field of genetic medicine."

DMD is a rare and severe genetic disorder that affects boys and young men. It is associated with errors in the gene for dystrophin, a protein that plays a key structural role in muscle fibers. Patients with DMD lack functional dystrophin, and regular activity causes progressive muscle damage leading to weakness, loss of ambulation, respiratory and cardiac dysfunction, and eventually premature death. There are no approved treatments.

Exon-skipping is an innovative disease-modifying treatment approach designed to skip an exon in the dystrophin gene, thereby enabling the repair of specific genetic mutations and the production of a functional, but shorter, form of dystrophin. Sarepta currently has four exon-skipping programs in DMD addressing patients with genotypes amenable to skipping of exons 51, 45, 50 and 53.

Under the terms of the agreement, UWA is eligible to receive up to $7.1 million in upfront and development milestone payments, as well as a low single-digit royalty on net sales of all approved medicines under the collaboration. Additional financial terms were not disclosed.

About Duchenne Muscular Dystrophy

DMD is an X-linked rare, degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs eventually spreads to the arms, neck and other areas. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and death usually occurs before the age of 30.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com .

About the University of Western Australia

The University of Western Australia is a leading Australian research-based institution that ranks internationally among the world's top 100 universities. UWA is a member of Australia's Group of Eight top research universities, and one of only two Australian members of the Worldwide Universities Network, a partnership of 18 research-led universities from Europe, Africa, the Americas and the Asia-Pacific. The University is also a foundation member of the Matariki Network of high-quality, research-intensive universities with a particular focus on student experience. The campus is based in Perth, capital city of Western Australia.

Forward Looking Statement

This press release contains forward-looking statements. These forward-looking statements generally can be identified by use of words such as "believes or belief," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," "advance" and similar expressions. These forward-looking statements include statements about the development of eteplirsen and its potential commercialization as well as statements regarding the potential of Sarepta's other pipeline candidates.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: subsequent clinical trials may fail to demonstrate the safety and efficacy of eteplirsen or replicate results; treatment of patients with DMD using eteplirsen over a longer duration may not lead to significant clinical benefit; any of Sarepta's drug candidates, including eteplirsen, may fail in development, may not receive required regulatory approvals, or may not become commercially viable due to delays or other reasons; our enhanced intellectual property rights may provide us neither the ability to exclude competitors nor freedom to commercialize our product candidates; and those identified under the heading "Risk Factors" in Sarepta's Annual Report on Form 10-K for the year ended December 31, 2012, and filed with the Securities and Exchange Commission.

Any of the foregoing risks could materially and adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the Company's filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Sarepta Investor Contact: Erin Cox +1.857.242.3714 Email Contact Sarepta Media Contact: Jim Baker +1.857.242.3710 Email Contact UWA Media Contact: Simon Handford +61.8.6488.8187 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 49

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 139

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 93

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 110

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 69

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading